Drug makers’ downsizing moves continue unabated in Japan. In the past three months alone, it was revealed that voluntary redundancy programs were being planned or launched for Pfizer, MSD, and Sanofi, affecting a total of over 600 staffers mainly in…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Proposes Creation of Disease Registry to Employ Medical Data
June 5, 2018
- New JPMA Chief Calls for Scrapping PMP Company Criteria
June 1, 2018
- Sawai President Elected New Generic Industry Chief
May 30, 2018
- Drug Damage Watchdog Submits Opinion to Health Ministry, Opposing Current Conditional Early Approval System
May 30, 2018
- Big Data Analysis Finds Low Generic Drug Use Rate among Healthcare Professionals: Kyokai Kenpo
May 28, 2018
- Daiichi Sankyo CEO Nakayama Appointed as New President of JPMA
May 25, 2018
- Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
- PhRMA Vision Report Stresses Innovation as Investment for Healthier Lifespans
May 17, 2018
- Over 80% Concerned about Restrictions on Access to Prescription Drugs: PhRMA Survey
May 15, 2018
- Drug Damage Watchdog Calls for 3rd Party Long-Term Investigation for HPV
May 2, 2018
- PhRMA/EFPIA Deeply Concerned about MOF Pitch on Stringent CEA Application
April 26, 2018
- PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says
April 20, 2018
- Asian Industry Groups Agree to Use Common Site Master File for Plant Inspections
April 16, 2018
- PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
April 13, 2018
- Company Category Criteria for Price Maintenance Premium Tough on Ophthalmic Drug Makers: Industry Group
April 9, 2018
- Japan CRO Association Members Deliver Actual 8.1% Sales Surge in 2017
April 5, 2018
- GHIT Fund to Make New Investment of 1.66 Billion Yen for Development of Therapies and Vaccines
March 30, 2018
- 100 Infusion Products Got Price Raises under Unprofitability Re-Pricing, but Drastic Pricing Reform Still Necessary: IV Solution Society
March 26, 2018
- Americas Chief James Robinson Leaves Astellas, What Will Happen to PhRMA Treasurer Seat?
March 20, 2018
ページ
As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In my home country of Australia, there is a famous candy called “Minties”. Minties has a long-running advertising campaign, presenting comical situations, with the caption, “It’s moments like these.” The phase has become part of the Aussie vernacular, meaning in…